- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ixekizumab significantly relieves back pain, morning stiffness and disease activity in psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory condition predominantly affecting peripheral joints. The disease has heterogeneous manifestations, including peripheral arthritis, axial arthritis, enthesitis, dactylitis, and skin and nail psoriasis. Some patients with psoriatic arthritis also experience symptoms relating to the spine and sacroiliac joint (axial manifestations). Ixekizumab, a monoclonal antibody, targets IL-17A (pathogenesis of PsA) with high affinity.
Atul Deodhar, in his recent study, wrote, “Ixekizumab (IXE) is a potentially therapeutic option in managing patients with psoriatic arthritis (PsA). The drug improves axial manifestations, including back pain and morning stiffness in the spine, disease activity, and fatigue (52 weeks). This study is published in Therapeutic Advances in Musculoskeletal Disease.
Among PsA patients, those with axial manifestations experience greater severity of PsA-related symptoms, which include enthesitis, dactylitis, and TJC. In this study, a team of researchers determined the efficacy of ixekizumab (IXE) up to 52 weeks in reducing axial symptoms in patients with a history of axial manifestations in a post hoc analysis of two pooled phase III clinical trials.
Patients with axial manifestations from SPIRIT-P1 and SPIRIT-P2 trials were defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 (Q2; back pain)] total score ⩾four and average of BASDAI Q5 + Q6 (morning stiffness) ⩾4 at baseline. IXE efficacy was evaluated at weeks 16, 24, and 52 using separate BASDAI questions, total BASDAI and modified BASDAI, Ankylosing Spondylitis Disease Activity Score (ASDAS), and 50% improvement in BASDAI (BASDAI50) response.
The key results of the study are:
- Among 313 PsA patients with axial manifestations at baseline, there were more significant improvements in back pain and morning stiffness at weeks 16 and 24 in those receiving IXE versus placebo.
- In those receiving IXE, there were greater improvements in BASDAI individual scores and total scores, mBASDAI, and ASDAS compared with placebo.
- Disease activity improved in ixekizumab-treated patients than in placebo.
- More IXE-treated patients achieved BASDAI50 at weeks 16 and 24 versus placebo.
- IXE effect was sustained at week 52.
Concluding further, IXE improves axial symptoms in patients with active PsA. It improves symptoms of back pain and morning stiffness in these patients.
The co-author of this study Gladman et al said, "Our study had the major advantage of adding two sensitivity analysis subgroups, allowing for additional data interpretation. We noted these improvements regardless of age, whether less than 45 years and regardless of inflammation level."
The study's major limitation includes a lack of a validated definition of axial and non-consideration of the HLA-B27 status or radiographs of the sacroiliac joint spine.
Further reading:
Deodhar A, Gladman D, Bolce R, Sandoval D, Park SY, Leage SL, Nash P, Poddubnyy D. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Ther Adv Musculoskelet Dis. 2023 Aug 24;15:1759720X231189005. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462424/
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751